


# PRODUCT INFORMATION



## LOXO-292

Item No. 33515

**CAS Registry No.:** 2152628-33-4  
**Formal Name:** 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]-pyrazolo[1,5-a]pyridine-3-carbonitrile  
**Synonyms:** ARRY-192, Selpercatinib  
**MF:** C<sub>29</sub>H<sub>31</sub>N<sub>7</sub>O<sub>3</sub>  
**FW:** 525.6  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 239, 335 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

LOXO-292 is supplied as a crystalline solid. A stock solution may be made by dissolving the LOXO-292 in the solvent of choice, which should be purged with an inert gas. LOXO-292 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of LOXO-292 in these solvents is approximately 1 mg/ml.

### Description

LOXO-292 is an inhibitor of the receptor tyrosine kinase RET.<sup>1</sup> It inhibits the phosphorylation of a KIF5B-RET fusion protein expressed in HEK293 cells (IC<sub>50</sub> = 4 nM). LOXO-292 selectively inhibits proliferation of cancer cells containing RET mutations or gene fusions, including RET<sup>M918T</sup>-containing MZ-CRC-1 medullary thyroid and CCDC6-RET gene fusion-positive TPC-1 thyroid cancer cells, by 20 to 1,700-fold. It improves survival in a CCDC6-RET gene fusion-positive orthotopic patient-derived xenograft (PDX) mouse model of brain cancer when administered at a dose of 30 mg/kg. Formulations containing LOXO-292 have been used in the treatment of RET mutation- or gene fusion-positive lung or thyroid cancers.

### Reference

1. Subbiah, V., Velcheti, V., Tuch, B.B., *et al.* Selective RET kinase inhibition for patients with RET-altered cancers. *Ann. Oncol.* **29**(8), 1869-1876 (2018).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM